UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

AMNEAL PHARMACEUTICALS and PAR PHARMACEUTICAL, INC., LLC, Petitioner,

v.

JAZZ PHARMACEUTICALS INTERNATIONAL LIMITED,
JAZZ PHARMACEUTICALS, INC.,
JAZZ PHARMACEUTICALS IRELAND LIMITED,
and JAZZ PHARMACEUTICALS INTERNATIONAL III LIMITED,
Patent Owner.

Case IPR2015-01903 Patent 8,731,963

Mailed: September 30, 2015

Before PATRICK E. BAKER, Trial Paralegal.

NOTICE OF FILING DATE ACCORDED TO PETITION
AND
TIME FOR FILING PATENT OWNER PRELIMINARY RESPONSE



The petition for *inter partes* review in the above proceeding has been accorded the filing date of September 14, 2015.

Patent Owner may file a preliminary response to the petition no later than three months from the date of this notice. The preliminary response is limited to setting forth the reasons why the requested review should not be instituted. Patent Owner may also file an election to waive the preliminary response to expedite the proceeding. For more information, please consult the Office Patent Trial Practice Guide, 77 Fed. Reg. 48756 (Aug. 14, 2012), which is available on the Board Web site at http://www.uspto.gov/PTAB.

Patent Owner is advised of the requirement to submit mandatory notice information under 37 C.F.R. § 42.8(a)(2) within 21 days of service of the petition.

The parties are encouraged to use the heading on the first page of this Notice for all future filings in the proceeding.

The parties are advised that under 37 C.F.R. § 42.10(c), recognition of counsel *pro hac vice* requires a showing of good cause. The parties are authorized to file motions for *pro hac vice* admission under 37 C.F.R. § 42.10(c). Such motions shall be filed in accordance with the "Order -- Authorizing Motion for Pro Hac Vice Admission" in Case IPR2013-00639, Paper 7, a copy of which is available on the Board Web site under "Representative Orders, Decisions, and Notices."

The parties are reminded that unless otherwise permitted by 37 C.F.R. § 42.6(b)(2), all filings in this proceeding must be made electronically in the Patent Review Processing System (PRPS), accessible from the Board Web site at http://www.uspto.gov/PTAB. To file documents, users must first obtain a user ID and password by registering with PRPS. Information



IPR2015-01903 Patent 8,731,963

regarding how to register with and use PRPS is available at the Board Web site.

If there are any questions pertaining to this notice, please contact Patrick E. Baker at 571-272-6192 or the Patent Trial and Appeal Board at 571-272-7822.



IPR2015-01903 Patent 8,731,963

PETITIONER:

Aziz Burgy
Bradford C. Frese
ARENT FOX LLP
Aziz.Burgy@arentfox.com
Bradford.Frese@arentfox.com

PATENT OWNER:

SCHWEGMAN LUNDBERG & WOESSNER/JAZZ PHARMACEUTICAL P.O. Box 2938
Minneapolis, MN 55402

F. Dominic Cerrito
Eric C. Stops
Gabriel P. Brier
QUINN EMANUEL URQUHART & SULLIVAN LLP
51 Madison Avenue
22nd Floor
New York, NY 10010

Richard G. Greco RICHARD G. GRECO PC 909 State Street, Suite 700 Albany, New York 12207

John V. Biernacki JONES DAY North Point 901 Lakeside Avenue Cleveland, OH 44114

